# Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

> **NCT03488810** · PHASE3 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Prostate Cancer

## Interventions

- **OTHER:** Radiation Therapy
- **DRUG:** Apalutamide
- **DRUG:** Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
- **DRUG:** Non-steroidal anti-androgen

## Key facts

- **NCT ID:** NCT03488810
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-10
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Extended study timelines and additional budget could no longer be supported.
- **Last updated:** 2020-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488810, "Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03488810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*